DMC Recommends AzurRx Continues Gastrointestinal Infections COVID-19 Study

(RTTNews) - AzurRx BioPharma Inc. (AZRX) said that an independent data monitoring committee or DMC approved initiating patient enrollment in Part 2 of the ongoing RESERVOIR Phase 2 clinical trial evaluating FW-1022 as a treatment for COVID-19-related gastrointestinal infections.

FW-1022 is a proprietary, oral, tablet formulation of micronized niclosamide developed to remove SARS-CoV-2, the virus that causes COVID-19, from the gastrointestinal tract.

The committee's recommendation followed its review of safety data collected from 9 patients enrolled in Part 1 of the RESERVOIR trial. During Part 2, the trial will enroll up to 150 patients at clinical trial sites in the U.S., Ukraine and India and focus on demonstrating the efficacy of FW-1022 in clearing the COVID virus from the GI tract and expanding previous safety observations.

The study data is expected during the first quarter of 2022.